These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28969862)

  • 21. [The translocation carcinoma: A pediatric renal tumor also in adults].
    Bruder E; Moch H
    Pathologe; 2016 Mar; 37(2):159-65. PubMed ID: 26972595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma.
    Pei J; Cooper H; Flieder DB; Talarchek JN; Al-Saleem T; Uzzo RG; Dulaimi E; Patchefsky AS; Testa JR; Wei S
    Mod Pathol; 2019 May; 32(5):710-716. PubMed ID: 30622287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.
    Xu Y; Rao Q; Xia Q; Shi S; Shi Q; Ma H; Lu Z; Chen H; Zhou X
    Int J Clin Exp Pathol; 2015; 8(3):2690-9. PubMed ID: 26045774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas.
    Harada S; Caliò A; Janowski KM; Morlote D; Rodriguez Pena MD; Canete-Portillo S; Harbi D; DeFrank G; Magi-Galluzzi C; Netto GJ; Martignoni G; Mackinnon AC
    Mod Pathol; 2021 Nov; 34(11):2055-2063. PubMed ID: 34148064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis.
    Yang B; Duan H; Cao W; Guo Y; Liu Y; Sun L; Zhang J; Sun Y; Ma Y
    Mod Pathol; 2019 Oct; 32(10):1521-1535. PubMed ID: 31175325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR.
    Argani P; Laé M; Hutchinson B; Reuter VE; Collins MH; Perentesis J; Tomaszewski JE; Brooks JS; Acs G; Bridge JA; Vargas SO; Davis IJ; Fisher DE; Ladanyi M
    Am J Surg Pathol; 2005 Feb; 29(2):230-40. PubMed ID: 15644781
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel partner of TFE3 in the Xp11 translocation renal cell carcinoma: clinicopathological analyses and detection of EWSR1-TFE3 fusion.
    Fukuda H; Kato I; Furuya M; Tanaka R; Takagi T; Kondo T; Nagashima Y
    Virchows Arch; 2019 Mar; 474(3):389-393. PubMed ID: 30552521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity.
    Argani P; Reuter VE; Zhang L; Sung YS; Ning Y; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Nov; 40(11):1484-1495. PubMed ID: 27565001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Xp11 neoplasm with melanocytic differentiation of the prostate harbouring the novel NONO-TFE3 gene fusion: report of a unique case expanding the gene fusion spectrum.
    Wang XT; Xia QY; Ni H; Wang ZY; Ye SB; Li R; Wang X; Lv JH; Shi SS; Ma HH; Lu ZF; Shen Q; Zhou XJ; Rao Q
    Histopathology; 2016 Sep; 69(3):450-8. PubMed ID: 26844676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma.
    Caliò A; Brunelli M; Segala D; Pedron S; Tardanico R; Remo A; Gobbo S; Meneghelli E; Doglioni C; Hes O; Zampini C; Argani P; Martignoni G
    Mod Pathol; 2018 Mar; 31(3):474-487. PubMed ID: 29052596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
    Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
    [No Abstract]   [Full Text] [Related]  

  • 32. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
    Martignoni G; Gobbo S; Camparo P; Brunelli M; Munari E; Segala D; Pea M; Bonetti F; Illei PB; Netto GJ; Ladanyi M; Chilosi M; Argani P
    Mod Pathol; 2011 Oct; 24(10):1313-9. PubMed ID: 21602817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.
    Wyvekens N; Rechsteiner M; Fritz C; Wagner U; Tchinda J; Wenzel C; Kuithan F; Horn LC; Moch H
    Virchows Arch; 2019 May; 474(5):625-631. PubMed ID: 30706129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the mit transcription factor family.
    Ramphal R; Pappo A; Zielenska M; Grant R; Ngan BY
    Am J Clin Pathol; 2006 Sep; 126(3):349-64. PubMed ID: 16880148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TFEB rearranged renal cell carcinoma. A clinicopathologic and molecular study of 13 cases. Tumors harboring MALAT1-TFEB, ACTB-TFEB, and the novel NEAT1-TFEB translocations constantly express PDL1.
    Caliò A; Harada S; Brunelli M; Pedron S; Segala D; Portillo SC; Magi-Galluzzi C; Netto GJ; Mackinnon AC; Martignoni G
    Mod Pathol; 2021 Apr; 34(4):842-850. PubMed ID: 33208882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect.
    Kuroda N; Mikami S; Pan CC; Cohen RJ; Hes O; Michal M; Nagashima Y; Tanaka Y; Inoue K; Shuin T; Lee GH
    Histol Histopathol; 2012 Feb; 27(2):133-40. PubMed ID: 22207547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
    Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
    Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological Findings on 28 Cases with XP11.2 Renal Cell Carcinoma.
    Kuthi L; Somorácz Á; Micsik T; Jenei A; Hajdu A; Sejben I; Imre D; Pósfai B; Kóczián K; Semjén D; Bajory Z; Kulka J; Iványi B
    Pathol Oncol Res; 2020 Oct; 26(4):2123-2133. PubMed ID: 31955345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
    Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
    Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiT family translocation renal cell carcinoma in an elderly male.
    Prachi ; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(3):553-555. PubMed ID: 34341271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.